Toxicity Management: CAR-Ts Versus Bispecific T-Cell Engagers

Toxicity Management: CAR-Ts Versus Bispecific T-Cell Engagers

Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T TherapiesПодробнее

Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies

T-Cell Engagers: targets, challenges and opportunityПодробнее

T-Cell Engagers: targets, challenges and opportunity

CAR-T cell therapy in lymphomaПодробнее

CAR-T cell therapy in lymphoma

CAR-T Cell Therapies - Where are we now (edited for unpublished data)Подробнее

CAR-T Cell Therapies - Where are we now (edited for unpublished data)

Which Patients Are Not Well Suited for CAR-T Therapy?Подробнее

Which Patients Are Not Well Suited for CAR-T Therapy?

What Is the Future for CAR-T in Multiple Myeloma?Подробнее

What Is the Future for CAR-T in Multiple Myeloma?

Myeloma Panel Compares Real-World Versus Clinical Trial Data for CAR-Ts, BispecificsПодробнее

Myeloma Panel Compares Real-World Versus Clinical Trial Data for CAR-Ts, Bispecifics

Myeloma Treatment Selection: CAR-T Versus Bispecific T-Cell Engagers, Bridging Therapy OptionsПодробнее

Myeloma Treatment Selection: CAR-T Versus Bispecific T-Cell Engagers, Bridging Therapy Options

Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MDПодробнее

Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MD

Newest Immunotherapies for Blood Cancer! What to Know about Bispecifics & CAR T-Cell TherapyПодробнее

Newest Immunotherapies for Blood Cancer! What to Know about Bispecifics & CAR T-Cell Therapy

CAR-T Cells: Engineered Cancer Killers, Mechanism of ActionПодробнее

CAR-T Cells: Engineered Cancer Killers, Mechanism of Action

Bispecific anti-CD20, anti-CD19 CAR-Ts for R/R NHLПодробнее

Bispecific anti-CD20, anti-CD19 CAR-Ts for R/R NHL

Antibody Drug Development Summit Autumn 2021 - James Keck, Ph.D.Подробнее

Antibody Drug Development Summit Autumn 2021 - James Keck, Ph.D.

Case Based Clinical Updates in Hematology | 2023 Community Cases Tampa ConferenceПодробнее

Case Based Clinical Updates in Hematology | 2023 Community Cases Tampa Conference

Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UABПодробнее

Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UAB

Looking into the future of CAR-T therapy: cardiac fibrosis, infections & autoimmune diseasesПодробнее

Looking into the future of CAR-T therapy: cardiac fibrosis, infections & autoimmune diseases

Approved and emerging CAR-Ts in multiple myelomaПодробнее

Approved and emerging CAR-Ts in multiple myeloma

Dual-Targeting CARs and Allogeneic CARs Are Options to “Keep Myeloma on its Toes”Подробнее

Dual-Targeting CARs and Allogeneic CARs Are Options to “Keep Myeloma on its Toes”